A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

NCT01599949 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Ibrutinib

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]